Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Albuterol
Drug ID BADD_D00056
Description Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400]
Indications and Usage Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.[Label,F3265,F3268]
Marketing Status approved; vet_approved
ATC Code R03CC02; R03AC02
DrugBank ID DB01001
KEGG ID D02147
MeSH ID D000420
PubChem ID 2083
TTD Drug ID D0K5CB
NDC Product Code 69543-291; 64980-442; 71205-899; 69238-1345; 70710-1062; 59651-333; 70771-1511; 71205-898; 59651-334; 63629-2611; 64980-443; 69238-1344; 70710-1061; 70771-1512; 69543-290
UNII QF8SVZ843E
Synonyms Albuterol | Salbutamol | 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol | Ventolin | Sultanol | Albuterol Sulfate | Proventil
Chemical Information
Molecular Formula C13H21NO3
CAS Registry Number 18559-94-9
SMILES CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular fibrillation02.03.04.0080.000011%
Ventricular tachycardia02.03.04.0100.000023%
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Wheezing22.03.01.0090.000466%
Musculoskeletal disorder15.03.05.025--Not Available
Axillary pain08.01.08.0150.000006%Not Available
Paradoxical drug reaction08.06.01.0140.000006%Not Available
Emotional distress19.04.02.008--Not Available
Nocturnal dyspnoea22.02.01.019; 02.11.05.0090.000012%Not Available
General physical health deterioration08.01.03.0180.000030%Not Available
Tachyarrhythmia02.03.02.0080.000008%Not Available
Muscle fatigue15.05.03.0060.000008%Not Available
Muscle tightness15.05.03.0070.000012%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000012%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000006%Not Available
Exercise tolerance decreased08.01.03.0360.000015%Not Available
Respiratory tract congestion22.02.07.0030.000024%Not Available
Nasal discomfort22.12.03.0120.000038%Not Available
Cardiac flutter02.03.02.0120.000011%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.000028%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.000019%Not Available
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.0070.000012%
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000015%Not Available
Foetal death18.01.02.003; 08.04.01.0110.000011%
Haemorrhage24.07.01.002--Not Available
Pulmonary mass22.02.07.0040.000006%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000031%Not Available
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene